Key Metrics
6.5
CiteScore
CiteScore
CiteScore measures average citations received per document published in the serial.
1.15
SNIP
SNIP
Source Normalized Impact per Paper measures actual citations received relative to citations expected for the serial’s subject field.
Journal Specifications
| Overview | |
| Publisher | DOVE MEDICAL PRESS LTD |
| Language | English |
| Frequency | Continuous publication |
| Article Processing Charges | USD 2390 |
| Publication Time | 16 |
| Editorial Review Process | Anonymous peer review |
| General Details | |
| Language | English |
| Frequency | Continuous publication |
| Publication Start Year | 2008 |
| Publisher URL | Visit website |
| Website URL | Visit website |
| Publication Details | |
| Plagiarism | Visit website |
| Waiver Policy | Visit website |
| Publication Time | 16 |
| Article Processing Charges | USD 2390 |
| Editorial Review Detail | |
| Editorial Team | Visit website |
| Review Process | Anonymous peer review |
| Review Url | Visit website |
| Information for authors | |
| Author instructions | Visit website |
| Copyright Details | Visit website |
| Deposit Policy | Sherpa/Romeo |
| License type | CC BY, CC BY-NC |
| OA statement | Visit website |
Planning to publish in Lung Cancer: Targets and Therapy ?
Upload your Manuscript to get
- Degree of match
- Common matching concepts
- Additional journal recommendations
Looking for the right journals to submit your mansucript?
Upload your manuscript and get a submission readiness score and other journal recommendations.
Check my PaperRecently Published Papers
-
Full paper
HMGB1 Expression Levels Correlate with Response to Immunotherapy in Non-Small Cell Lung Cancer.
- 1 May 24
- Lung Cancer (Auckland, N.Z.)
-
Full paper
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
- 1 Apr 24
- Lung Cancer (Auckland, N.Z.)
-
Full paper
The Butterfly Flies - Practice Changing Results of PAPILLON, First Line Chemotherapy and Amivantamab for the Treatment of NSCLC Patients with EGFR Exon 20 Insertions.
- 1 Apr 24
- Lung Cancer (Auckland, N.Z.)
-
Full paper
Effectiveness and Safety of Anlotinib Combined with PD-1 Blockades in Patients with Previously Immunotherapy Treated Advanced Non-Small Cell Lung Cancer: A Retrospective Exploratory Study.
- 1 Mar 24
- Lung Cancer (Auckland, N.Z.)
-
Full paper
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver.
- 1 Feb 24
- Lung Cancer (Auckland, N.Z.)
-
Full paper
Innovative Techniques in Video-Assisted Thoracoscopic Surgery: Lu's Approach.
- 1 Feb 24
- Lung Cancer (Auckland, N.Z.)
Scite analysis
Powered by scite_
179 articles received 1.9k citations see all
- 79 Supporting
- 1,802 Mentioning
- 12 Contrasting
Editorial notices
- 0 Retractions
- 0 Withdrawals
- 0 Corrections
- 0 Errata
- 0 Expression of Concern
FAQs
How long has Lung Cancer: Targets and Therapy been actively publishing?
Lung Cancer: Targets and Therapy has been in operation since 2008 till date.
What is the publishing frequency of Lung Cancer: Targets and Therapy ?
Lung Cancer: Targets and Therapy published with a Continuous publication frequency.
How many articles did Lung Cancer: Targets and Therapy publish last years ?
In 2023, Lung Cancer: Targets and Therapy published 12 articles.
What is the eISSN & pISSN for Lung Cancer: Targets and Therapy ?
For Lung Cancer: Targets and Therapy,eISSN is 1179-2728 and pISSN is1179-2728.
What is Citescore for Lung Cancer: Targets and Therapy ?
Citescore for Lung Cancer: Targets and Therapy is 6.5.
What is SNIP score for Lung Cancer: Targets and Therapy ?
SNIP score for Lung Cancer: Targets and Therapy is 1.15.
Who is the publisher of Lung Cancer: Targets and Therapy ?
DOVE MEDICAL PRESS LTD is the publisher of Lung Cancer: Targets and Therapy.